Dr.Reddy’s Laboratories (DRL) has launched anti-cancer injection in the United States market.
Dr. Reddy’s Melphalan Hydrochloride for Injection, a therapeutic equivalent generic version of Alkeran (melphalan hydrochloride) for Injection has been approved by the US Food and Drug Administration (USFDA), DRL said in a statement.
The drug contains one single-dose clear glass vial of freeze-dried melphalan hydrochloride equivalent to 50 mg melphalan and one 10 mL clear glass vial of sterile diluent.
The Alkeran brand and generic had US sales of approximately USD 107 million MAT ( Moving Auula Turnover) in the last 12 months ending October 2017.
The drug should be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.